Arcturus Receives FDA Approval of Phase 2 Vaccine Trials
Tuesday, January 12, 2021
Arcturus Therapeutics (Nasdaq: ARCT) received approval from the Food and Drug Administration (FDA) to proceed with Phase 2 trials of its COVID-19 vaccine candidate, LUNAR-COV19...
Take 1 minute to subscribe and you'll get this story immediately, plus:
Already a subscriber? Sign in
- 52 weekly issues
- Subscriber-only digital content every business day, plus full access to SDBJ.com archives
- Book of Lists — the most comprehensive business resource in San Diego
- San Diego 500 — influential business leaders you need to know